Literature DB >> 28660593

Is Obesity the New Hypertension? Parallels in the Evolution of Obesity and Hypertension as Recognized Disease States.

Devika Umashanker1, Alpana P Shukla1, Katherine H Saunders1, Louis J Aronne2.   

Abstract

Obesity and hypertension are recognized disease states that share many similarities including complex physiology, therapeutic response to both lifestyle modification and pharmacotherapy, and the need for long-term management. Both were initially believed to be disorders of lifestyle rather than true disease entities, and initial efforts at developing medical and surgical therapies were criticized. Ultimately, both have proven to be amenable to treatments that control their underlying physiology. Both hypertension and obesity have complex pathophysiology involving multiple regulatory pathways that may require combination therapies in addition to lifestyle modification to reach therapeutic goals. While hypertension is now a mature field practiced widely in primary care with the availability of 127 antihypertensive drugs, the specialty of obesity medicine is still in its infancy and growing in terms of management and development of medications, devices, and minimally invasive surgical interventions. Although the medical antiobesity armamentarium is relatively limited at present to six FDA-approved drugs, the development of combination pharmacotherapies with lower doses of component agents has improved efficacy and tolerability. As we look to the future of obesity medicine, hypertension can be used as a template to educate the public, fund research, and develop further treatment strategies.

Entities:  

Keywords:  Hypertension; Lifestyle modification; Obesity; Pharmacotherapy

Mesh:

Substances:

Year:  2017        PMID: 28660593     DOI: 10.1007/s11883-017-0671-0

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  6 in total

1.  Annual medical spending attributable to obesity: payer-and service-specific estimates.

Authors:  Eric A Finkelstein; Justin G Trogdon; Joel W Cohen; William Dietz
Journal:  Health Aff (Millwood)       Date:  2009-07-27       Impact factor: 6.301

2.  Heart disease and stroke statistics--2015 update: a report from the American Heart Association.

Authors:  Dariush Mozaffarian; Emelia J Benjamin; Alan S Go; Donna K Arnett; Michael J Blaha; Mary Cushman; Sarah de Ferranti; Jean-Pierre Després; Heather J Fullerton; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Simin Liu; Rachel H Mackey; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Paul Muntner; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Graham Nichol; Latha Palaniappan; Dilip K Pandey; Mathew J Reeves; Carlos J Rodriguez; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Joshua Z Willey; Daniel Woo; Robert W Yeh; Melanie B Turner
Journal:  Circulation       Date:  2014-12-17       Impact factor: 29.690

3.  Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg.

Authors: 
Journal:  JAMA       Date:  1970-08-17       Impact factor: 56.272

4.  Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis.

Authors:  Bradley C Johnston; Steve Kanters; Kristofer Bandayrel; Ping Wu; Faysal Naji; Reed A Siemieniuk; Geoff D C Ball; Jason W Busse; Kristian Thorlund; Gordon Guyatt; Jeroen P Jansen; Edward J Mills
Journal:  JAMA       Date:  2014-09-03       Impact factor: 56.272

Review 5.  Indirect costs of obesity: a review of the current literature.

Authors:  J G Trogdon; E A Finkelstein; T Hylands; P S Dellea; S J Kamal-Bahl
Journal:  Obes Rev       Date:  2008-03-05       Impact factor: 9.213

Review 6.  Timeline of History of Hypertension Treatment.

Authors:  Mohammad G Saklayen; Neeraj V Deshpande
Journal:  Front Cardiovasc Med       Date:  2016-02-23
  6 in total
  1 in total

Review 1.  There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.

Authors:  Michael E Makover; Michael D Shapiro; Peter P Toth
Journal:  Am J Prev Cardiol       Date:  2022-08-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.